We’re proud to launch our first Healthcare Collaboration Report—a survey that looked at American’s views of #healthcare, #drugdiscovery and #pandemic prevention. View the report today to learn more https://t.co/4btW63kbaQ #HealthcareCollabReport
Today we’re celebrating the connections formed at Charles River that have changed people's lives. Like Katja and Mikko, who bonded while volunteering for Kuopio's Recreation Committee. Follow us on Instagram (@criverlabs) to see more stories of work besties. #LIFEatCRL
1/3 Wonderful to finally be able to share our paper on the development and deployment of milasen, now online at https://t.co/wU4VtLvWNw. It’s accompanied by thoughtful commentary from Janet Woodcock and Peter Marks of the FDA (https://t.co/qxX0YnVqlg).
Rare #cancer isn’t actually rare. Over 95% of cancers fall under the “rare” categorization. David Hysong from
@Shepherd_bio opens the #CRLworldcon Day 2.
An honor to see Lauren Black, one of our collaborators in the development of customized therapeutics, at the #CRLworldcon. Looking forward to day 2!
@CRiverLabs#cureraredisease
“To those who say ‘impossible, impractical, unrealistic,’ we say: challenge accepted.” Great talk from Peter Smith of @Alnylam at #crlworldcon@CRiverLabs
Thank you, Matt for your talk on starting @gracescience and how you’re rethinking drug discovery. Finding a biomarker in earwax is such a simple, thoughtful idea. Keep up the good work! #crlworldcon@CRiverLabs
“The #microbiome responds immediately to what we eat, how we’re housed, our state of mind...” -Kim Tang @AxialBioTx. Fascinating insight during the panel at @CRiverLabs’s #Neuroinflammation Symposium. 🙌🏻
@dscounotte I’m very excited for your panel this afternoon! I find the impact of gut #microbiome on the brain to be equal parts fascinating and terrifying.
Want to be thoroughly (and appropriately) terrified before your next checkup? Read this spot-on thread. Part of why I am a huge proponent of being your own health advocate.
@JefAkst Any interest in hearing about the use of PARP inhibitors and immunotherapies in combination to treat BRCA-deficient cancers? Julia Schueler is giving an oral presentation this afternoon at 3:35 in A411. https://t.co/FTPCbhms0S
@StockwellSerena Well you are doing a great job of covering the show remotely! If the topic is of interest, feel free to email me ([email protected]) and I can connect you with Julia.
@StockwellSerena Any interest in hearing about the use of PARP inhibitors and immunotherapies in combination to treat BRCA-deficient cancers? Julia Schueler is giving an oral presentation this afternoon at 3:35 in A411. https://t.co/FTPCbhms0S